COMP <GO>
XENE vs MRK // EV/EBITDA & P/E VALUATION
Xenon Pharmaceuticals Inc. (NASDAQ) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: XENE 3
— MRK 11
■ METRIC PARITY
LAST: $37.41 (-0.35%) • MKT CAP: $3.64B
valuation
—
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
valuation
15.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (XENE VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | XENE | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 74.80% | -33.80 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 20.70% | -55.70 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -7.70% | 3.42% | -11.12 | MRK | /fcf-yield <GO> |
| Operating Margin | -36.70% | 34.30% | -71.00 | MRK | /operating-margins <GO> |
| Net Profit Margin | -34.00% | 28.10% | -62.10 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 7.70% | 1.30% | +6.40 | XENE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 5.19 | +20.81 | XENE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.20% | 6.60% | +0.60 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 44.3 | 56.9 | -12.58 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.10 | 0.92 | +0.18 | XENE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 29.0x | 18.4x | +10.60 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.64B | $361.02B | -$357.39B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | XENE REV | MRK REV | XENE GROSS % | MRK GROSS % | XENE FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $65.01B | — | 74.8% | -$279.9M | $12.36B |
| FY 2024 | $0 | $64.17B | — | 76.3% | -$184.5M | $18.10B |
| FY 2023 | $0 | $60.12B | — | 44.0% | -$151.1M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
XENE // BETA 1.10
MRK // BETA 0.92